Renalytix AI PLC ADR (RNLX) News
Filter RNLX News Items
RNLX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
RNLX News Highlights
- RNLX's 30 day story count now stands at 2.
- Over the past 17 days, the trend for RNLX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DRUG are the most mentioned tickers in articles about RNLX.
Latest RNLX News From Around the Web
Below are the latest news stories about RENALYTIX PLC that investors may wish to consider to help them evaluate RNLX as an investment opportunity.
Renalytix and Partners Awarded $10 Million Horizon Europe Grant to Advance Personalized Medicine in Treating CKD Throughout Europe and the United StatesAward for consortium of industry, academic and clinical research leaders to develop personalized drug response tests in chronic kidney diseaseLONDON and SALT LAKE CITY, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces the launch of PRIME-CKD*, a consortium of industry, academic and clinical research leaders, that aims to validate and implement in clinical practice, novel biomarker-based tests that predict response to existing drugs used by patients with chroni |
Renalytix Completes Agreement with Veterans Administration to Integrate KidneyIntelX Testing across all Electronic Health Record systemsSignificant milestone will make KidneyIntelX accessible to 960,000 veterans with chronic kidney diseaseLONDON and SALT LAKE CITY, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the execution of a Co-operative Research and Development Agreement (CRADA) with the U.S. Veterans Health Administration Innovation Ecosystem (VHA IE) to install the KidneyIntelX solution inside the VA Health System’s Cloud Infrastructure and interface it with the VA Electronic H |
Renalytix Plc (NASDAQ:RNLX) Q1 2023 Earnings Call TranscriptRenalytix Plc (NASDAQ:RNLX) Q1 2023 Earnings Call Transcript November 30, 2022 Operator: Good morning and welcome to the Renalytix Conference Call to review First Quarter Fiscal 2023 Financial Results. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, […] |
Primary Care Use of KidneyIntelX in Early Stage CKD Improved Clinical Care Delivery and OutcomesFirst-in-class bioprognostic™ KidneyIntelX provided clear direction for primary care physicians to slow or stop progression of chronic kidney disease in adult diabetes patientsLONDON and SALT LAKE CITY, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced additional highlights from the publication of data from a clinical utility study demonstrating that use of KidneyIntelX risk assessment in the primary care setting resulted in improved clinical decision mak |
Edited Transcript of RENX.L earnings conference call or presentation 30-Nov-22 1:30pm GMTQ1 2023 Renalytix PLC Earnings Call |
Published Real World Evidence Demonstrates KidneyIntelX™ Improved Clinical Decisions and Outcomes in High-Risk Patients with Early-Stage Diabetic Kidney DiseaseRisk scoring by KidneyIntelX resulted in a 4.5-fold increase in new drug prescriptions (for SGLT2 inhibitors) for high risk compared to low risk patients, an observed reduction of HbA1c levels in the highest risk patients, an overall increased use of antihypertensive therapeutics, and an observed early reduction in albumin to creatine ratio levels in the low and intermediate risk groups. KidneyIntelX risk assessment was incorporated into Mount Sinai Health System’s Ambulatory Care Pathway and it |
Renalytix to Report Financial Results for First Quarter Fiscal Year 2023 on November 30LONDON and SALT LAKE CITY, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that it will report its first quarter fiscal year 2023 financial results on Wednesday, November 30, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (GMT). Conference Call Deta |
Renalytix to Present at Stifel Healthcare ConferenceNEW YORK and SALT LAKE CITY, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will participate in the Stifel Healthcare Conference to be held November 15-16, 2022 at the Lotte New York Palace Hotel. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the Company’s website at https://investors.renalytix.com or via the webcast registration link below beginning at 3:35 p.m. Eastern Time on |
Renalytix Reports Full Year Fiscal 2022 ResultsLONDON and SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX), (LSE: RENX) an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces its full year results for the twelve months ended 30 June 2022. Highlights (includes post-period events): Regulatory & Reimbursement New commercial coverage in fiscal year 2022; 28 private insuranc |
Renalytix to Report Financial Results for Fourth Quarter and Full Year Fiscal 2022 on October 31NEW YORK and SALT LAKE CITY, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its fourth quarter and full year fiscal 2022 financial results on Monday, October 31, 2022, before market open. The Company will host a corresponding conference call and live webcast to discuss the financial results and key topics including business strategy, partnerships and regulatory and reimbursement processes, at 8:30 a.m. (ET) / 1:30 p.m. (BST). Co |